Piper Sandler Cuts Cardiff Oncology Price Target to $6.00

The firm maintains an overweight rating on the stock despite lowering its price target.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Cardiff Oncology (NASDAQ:CRDF) had its price target trimmed by Piper Sandler from $10.00 to $6.00 in a research note published on Wednesday. The firm currently has an overweight rating on the stock. Several other equity analysts have also recently commented on CRDF, with ratings ranging from 'buy' to 'sell'.

Why it matters

This price target cut by a major investment firm indicates potential challenges or uncertainties around Cardiff Oncology's near-term business outlook, despite the company's focus on novel cancer therapies. The mixed analyst ratings also suggest the stock may face volatility as the market weighs the company's progress and prospects.

The details

Piper Sandler reduced its price target on Cardiff Oncology from $10.00 to $6.00, though the firm maintained its overweight rating on the stock. Other analysts have also recently weighed in, with HC Wainwright reissuing a 'buy' rating and $10.00 target, Noble Financial starting coverage with an 'outperform' rating and $12.00 target, and Weiss Ratings giving a 'sell (d-)' rating.

  • The research note from Piper Sandler was published on Wednesday, February 28, 2026.

The players

Piper Sandler

An investment banking and institutional securities firm.

Cardiff Oncology

A clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies to treat cancer.

HC Wainwright

An investment banking and equity research firm.

Noble Financial

An investment research and management firm.

Weiss Ratings

An independent rating agency that provides research and analysis on stocks, mutual funds, and other financial products.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This price target cut by Piper Sandler suggests potential near-term challenges for Cardiff Oncology, despite the company's focus on novel cancer therapies. The mixed analyst ratings indicate the stock may face volatility as the market evaluates the company's progress and prospects.